Lumenis: Redefining What Medical Lasers Can Achieve

Standard fractional CO2 systems create columns of thermal damage in the epidermis and superficial dermis, typically reaching 1.0-1.6mm depth. SCAAR FX (Synergistic Coagulation and Ablation for Advanced Resurfacing) penetrates deeper into the reticular dermis — up to 4mm — bypassing the epidermal layer through a unique bridging mechanism. This allows treatment of deep scars, including burn scars and traumatic scars, with minimal surface disruption and faster healing compared to fully ablative approaches. A 2017 study in Lasers in Surgery and Medicine (Waibel et al.) documented a mean Vancouver Scar Scale improvement of 3.8 points in a cohort of 52 burn scar patients after 3 treatment sessions at 6-week intervals. It should be noted that results vary with scar type, depth, patient age, and skin type — patients with Fitzpatrick V-VI require conservative settings and have higher PIH risk.

The LightSheer handpiece uses negative pressure (vacuum) to draw the skin into the treatment window. This stretches the skin, bringing follicles closer to the surface and reducing the required fluence by approximately 50%. Lower fluence means less thermal energy delivered per pulse, which directly reduces pain perception. Additionally, the vacuum activates gate control pain pathways, further diminishing sensation. Most patients describe the experience as mild pressure rather than the snapping sensation typical of conventional diode systems. The practical result: faster treatments without topical anesthesia in most cases.

ROI depends on procedure volume, pricing, and platform selection. Based on data from our install base, a practice performing 15-20 treatments per week on the M22 platform typically reaches breakeven within 8-12 months. High-volume hair removal clinics using LightSheer report faster payback due to the speed advantage: treating a full back in under 15 minutes versus 45+ minutes on competitor devices translates directly to higher daily throughput. We provide a complimentary ROI analysis based on your specific practice parameters during the consultation process. We also note that results vary significantly by market — urban practices with higher pricing generally reach profitability faster than rural settings.

Yes, and transparency about this is important. Traditional IPL systems carry higher risk of post-inflammatory hyperpigmentation (PIH) on Fitzpatrick skin types IV-VI due to melanin absorption competing with the target chromophore. The M22 platform addresses this with adjustable cut-off filters (starting at 640nm for darker skin), allowing practitioners to avoid shorter wavelengths that interact more strongly with epidermal melanin. However, even with these safeguards, practitioners should perform test spots and follow conservative protocols for skin types V-VI. IPL is not the optimal modality for all conditions on all skin types — in some cases, Nd:YAG or diode wavelengths are more appropriate. Our clinical training program covers skin-type-specific protocols in detail.

This is one of the most debated questions in aesthetic medicine, and the honest answer is: it depends on your patient population. IPL (515-1200nm broadband) excels at treating superficial pigmented and vascular lesions in lighter skin types (Fitzpatrick I-III) because the broad spectrum targets multiple chromophores simultaneously. It is faster per session and covers larger treatment areas. However, IPL lacks selectivity for deeper structures and carries higher complication rates on melanin-rich skin. Nd:YAG (1064nm) penetrates deeper (4-6mm) and has lower melanin absorption, making it the safer choice for Fitzpatrick IV-VI patients and for deeper vascular targets like leg veins and reticular veins. The trade-off: Nd:YAG treatments are typically slower, require higher fluences, and may need more sessions for superficial conditions. Some practitioners argue IPL is outdated compared to specific-wavelength lasers; others counter that the M22's filter system provides wavelength selectivity comparable to dedicated platforms while offering more versatility. The evidence supports both positions depending on practice demographics. A practice in Scandinavia with predominantly Type I-II patients has different needs than a practice in Southeast Asia serving Type IV-V patients.